DARA BioSciences
Midatech Pharma US Inc. (DARA).
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
£20.0m Valuation: £20.0m | Acquisition | ||
| Total Funding | 000k | ||
Related Content
Fortovia Therapeutics is a healthcare company dedicated to advancing supportive care for cancer patients and their families. Operating in the oncology sector, Fortovia focuses on developing novel formulations of well-known compounds to provide alternatives to traditional cancer treatment methods. The company serves both patients and healthcare providers by offering a comprehensive portfolio aimed at alleviating treatment-related side effects such as oral mucositis, nausea, vomiting, and oropharyngeal candidiasis.
Fortovia's business model revolves around its Direct Rx Program, which aims to lower patient costs and improve access to essential medications. This program allows physicians to prescribe medications directly through Electronic Health Records (EHR) or faxed forms, ensuring that patients receive their treatments promptly and affordably. Fortovia generates revenue by selling its specialized medications and support products through this program, making it easier for patients to manage the financial burden of cancer treatment.
The company is committed to improving the quality of life for cancer patients by providing unrelenting support throughout their treatment journey. Fortovia's core values emphasize patient-centric care, innovation, and cost-effectiveness, making it a trusted partner for both healthcare providers and patients.
Keywords: oncology, supportive care, cancer treatment, Direct Rx Program, patient access, cost reduction, novel formulations, side effect management, healthcare providers, patient-centric.